Фибралакс

Quick links to important sections

Фибралакс

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Фибралакс

Property Description
Active ingredient Ispaghula Husk (Tunica Semenum Plantaginis Ovatae)
Form Granules or Powder
Pharmacological class Bulk-forming laxative
Common use Supporting regular bowel function
Origin Natural (Botanical)

What Type of Medicine is Фибралакс?

Фибралакс is a medicinal preparation classified as a bulk-forming laxative, a designation based on its gentle, physical mechanism of action within the gastrointestinal tract. This product is recognized as a herbal medicinal product due to its composition being entirely sourced from the Tunica Semenum Plantaginis Ovatae, or Psyllium Husk, which is the dried seed coat of the Plantago ovata plant. This botanical source is recognized for its high fiber content and superior hydration capabilities, supporting its role in promoting bowel regularity. Its function places it in a distinct pharmacological class, distinguishing it from chemically stimulating or osmotic agents. It is provided in solid forms, typically granules or powder, intended for oral administration after dispersion in an aqueous vehicle, serving as a single active ingredient product.

Composition: What is Ispaghula Husk (Psyllium) and its General Purpose?

The active ingredient in Фибралакс is Ispaghula Husk, which is the standard common name for Tunica Semenum Plantaginis Ovatae. The therapeutic efficacy is rooted in the high content of mucilage polysaccharides and dietary fibre within the husk. When mixed with water, these specialized components rapidly absorb fluid, forming a soft, cohesive gel. This resulting mass gently increases the stool bulk and moisture content, which is the core mechanism principle that aids the body. The general purpose of this action is to support the restoration of natural intestinal function and promote ease and regularity of elimination. This means the medicine helps the body achieve more predictable and comfortable bowel movements through a gentle, physical process.

Regulatory References

  1. Psyllium: MedlinePlus Drug Information

What side effects are possible with Фибралакс?

Possible Side Effects and Safety Information

The official safety documentation for Ispaghula Husk, the active ingredient in Фибралакс, outlines potential adverse reactions categorized primarily within Gastrointestinal Disorders and Immune System Disorders.

Adverse Reaction Scope

Classification Description (As per Regulatory Labels)
Common Effects Flatulence and Abdominal distension (bloating). These effects are noted to occur frequently during the initial few days of treatment but typically diminish with continued use.
System-Organ Classes Gastrointestinal Disorders; Immune System Disorders; Respiratory, Thoracic and Mediastinal Disorders; Eye Disorders; and Skin Disorders.
Serious Potential Reactions Intestinal obstruction, Oesophageal obstruction, Faecal impaction, Anaphylaxis, and Bronchospasm.

Key Safety Constraints

Due to the physical nature of this bulk-forming agent, a critical safety consideration is the risk of obstruction (oesophageal or intestinal), which is linked directly to administration with insufficient fluid. The product must be consumed with an adequate volume of water or other aqueous vehicle to mitigate this risk. Use is formally restricted in patients with existing gastrointestinal constrictions, confirmed intestinal obstruction, or faecal impaction.

Population and Interaction Notes

Official safety statements note that medical supervision may be required for use in older adults and debilitated patients due to the increased potential for obstruction. Use is not recommended in children below 6 years of age. Furthermore, this medication has the potential to delay or reduce the absorption of other oral medicines, requiring consideration for separation of dosing times.

Overdose and Emergency Response

Documented manifestations of an overdose of Ispaghula Husk are primarily gastrointestinal, including common symptoms such as abdominal discomfort and flatulence. Due to the nature of this bulk-forming agent, the most serious documented risks are centered on the potential for oesophageal obstruction or intestinal obstruction. These severe events are associated with symptoms like chest pain, vomiting, and difficulty in swallowing or breathing. A specific risk of choking is documented, particularly if the product is taken without sufficient fluid volume.

Regulatory documentation provides strict guidance on emergency actions. If an overdose is suspected or if symptoms of obstruction occur, users must seek immediate medical attention and are mandated to contact a doctor or a Poison Control Center right away.

For the management of overdose, no specific antidote is known. Official guidance directs treatment to be symptomatic and supportive, highlighting the necessity of maintaining adequate fluid intake to mitigate the physical effects. Furthermore, regulatory texts specify that the treatment of elderly patients and debilitated patients requires medical supervision due to their increased vulnerability to obstruction.

Therapeutic Uses of Фибралакс

What Фибралакс Treats: Main Uses and Benefits

Фибралакс is used to address symptoms that interfere with daily functioning due to bowel irregularity. Its applications include three key areas of supportive symptomatic relief. The established therapeutic applications include symptomatic relief for chronic and episodic constipation, stool softening in cases of haemorrhoids or anal fissures, and serving as an adjunct to diet in the management of hypercholesterolemia.

Managing Bowel Symptoms and Straining

This medication is applied in addressing symptoms related to intermittent or chronic difficulty with elimination, offering symptomatic relief for the irregularity characteristic of conditions such as constipation-predominant Irritable Bowel Syndrome (IBS-C). Its function includes the ability to help soften hard, dry stools, which is considered relevant in clinical situations where reducing straining is appropriate, particularly following anal or rectal surgery. This supportive effect assists with maintaining functional stability.

“The application of Ispaghula husk is primarily relevant in contexts where additional symptomatic support is needed to increase daily fibre intake, helping to ease the overall symptom burden associated with difficult elimination.”

Supportive Fibre Effect

This medication provides a crucial supportive fibre effect and is used as an adjunct to diet in the symptomatic management of elevated cholesterol. Furthermore, this supportive fibre effect may assist with managing symptoms of mild diarrhoea, as it is commonly applied in addressing symptoms related to loose stools.


Quick Fact: Relief for Straining

The medication helps ease symptoms of hard stools, which assists with reducing the physical discomfort and strain that can aggravate perianal conditions like haemorrhoids and anal fissures.

Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

The eligibility for using Фибралакс (Ispaghula Husk) is strictly defined by regulatory authorities based on age, physiological state, and pre-existing gastrointestinal integrity.

Populations for Whom Use is Contraindicated

Use of this medicine is prohibited for patients with:

  • Known hypersensitivity to Ispaghula Husk or any component of the product.
  • Existing or suspected intestinal obstruction (ileus), faecal impaction, or colonic atony.
  • Abnormal constrictions in the gastrointestinal tract or diseases of the oesophagus and cardia.
  • Difficulty in swallowing or any pre-existing throat problems.

Age and Condition-Based Eligibility

Category Eligibility Rule (Official Basis)
Approved Age Groups Adults and adolescents over 12 years are generally eligible.
Children (under 6 years) Use is not recommended due to insufficient data on safety and efficacy (for constipation).
Diabetic Patients Use must be under medical supervision as adjustment of anti-diabetic therapy may be required.
Elderly/Debilitated Treatment requires medical supervision.
Pregnancy/Lactation Use may be considered if dietary changes are unsuccessful, based on the low systemic absorption of the ingredient.

Eligibility is also restricted for patients experiencing undiagnosed abdominal symptoms, such as persistent changes in bowel habit, undiagnosed rectal bleeding, or failure to defecate after using a laxative.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Фибралакс (Ispaghula Husk) is defined by its ability to physically interfere with the absorption of other orally administered substances. This is classified as a pharmacokinetic interaction of the reduced absorption type, as documented in regulatory sources.

Interaction Scope Documented Interacting Substances
Affected Classes Cardiac Glycosides, Coumarin Derivatives (Oral Anticoagulants), Thyroid Hormones, Lithium salts, Carbamazepine, and Minerals (e.g., Iron).
Timing Rule To mitigate the potential for reduced exposure, all other oral medications must be administered at least 30 minutes to 1 hour before or 1 to 2 hours after the dose of Фибралакс.
Interaction Classification Official Regulatory Constraint
Contraindicated Combination Co-administration with medicinal products known to inhibit peristaltic movement, such as opioids, is strictly restricted due to the heightened risk of intestinal obstruction.
Pharmacodynamic Risk Use by diabetic patients requires specific medical supervision, as a potential pharmacodynamic interaction may necessitate adjustment of the anti-diabetic medication dose to maintain glucose stability.

Official Interaction Statements

  • The enteral absorption of drugs like cardiac glycosides (e.g., Digoxin) and coumarin derivatives may be delayed or reduced, leading to decreased plasma concentration.
  • The use of Thyroid Hormone preparations concomitantly requires medical supervision due to documented reduced absorption, noting that a dosage adjustment of the hormone may be necessary.
  • The mandatory timing separation rule is a fundamental regulatory requirement for virtually all oral medications to prevent the binding and subsequent reduced exposure effect.

Mechanism of Action

How Фибралакс Works

Фибралакс acts primarily within the gastrointestinal lumen via a non-systemic, localized mechanism. As a bulk-forming agent, the compound is neither absorbed into the systemic circulation nor does it engage chemical interactions with mucosal receptors or enzyme systems.

Local Modulation of Stool Hydration and Volume

Its core action involves the physical binding of a significant volume of free water directly within the intestinal tract, predominantly the colon. This process leads to the formation of a cohesive, hydrated hydrogel matrix. The physical consequence is an increase in the mass and pliability of the stool .

Mechanically Mediated Peristalsis Activation

The resultant increase in luminal volume functions as a mechanical stimulus, causing distension of the colonic wall. This distension initiates the intrinsic nervous system, triggering the peristaltic reflex. This cascade generates a sustained wave of muscle contractions that facilitate the propagated movement of the cohesive mass, thereby setting a sequence of physiological transit activity.

Dosage and Administration Information

How to use Фибралакс

The administration of Фибралакс follows specific steps to ensure proper use of this bulk-forming agent. The medicine is designated for the oral route only and is supplied as granules or powder that must always be prepared as a liquid suspension.

Dosing and Preparation: The standard adult single dose is 3.5 g of Ispaghula husk, which is typically taken twice daily—once in the morning and once in the evening. This dosage may be increased up to three times daily. Preparation requires mixing the dose with a full glass of water or other suitable fluid, generally defined as at least 150 mL (5 fl oz) to 240 mL (8 fl oz) of liquid, and consuming the mixture immediately. The product must never be taken in its dry form.

Timing and Duration: Doses should preferably be taken after meals and must be strictly separated from other oral medications by at least 30 minutes to an hour to prevent any impact on the absorption of other drugs. The last dose of the day should not be taken immediately before going to sleep. The full physiological effect usually begins after 12 to 24 hours, with the maximum effect appearing after 2 to 3 days of consistent use. For short-term use, consultation with a healthcare professional is advised if the established effect is not achieved within 3 days.

Population Rules: Dosing is not indicated to be modified for the elderly population. Children aged 12 years and over follow the adult dosage, while children aged 6 to 12 years are given a reduced dose, typically half to two-thirds of the adult amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Фибралакс


Evidence for use in Chronic Pain Management

Research has examined Фибралакс in people managing chronic pain, particularly those with chronic low back discomfort. The types of research conducted include short-term controlled clinical trials, which often compare Фибралакс to a placebo, and observational studies that monitor how symptoms are measured in a more natural, daily-life setting. These studies used measurement tools such as pain intensity scores and assessments of physical function to monitor outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Studies described how symptoms were reported in the observed populations over defined time intervals, primarily lasting between four and twelve weeks. Research reports changes measured during the study period, which included patient-reported outcomes describing perceived discomfort. Measurements varied across some studies, contributing to the understanding that evidence quality varies across the collected data.


Evidence for use in Generalized Anxiety Disorder

Фибралакс was evaluated in controlled clinical trials, including larger Phase 3 and Phase 4 studies, in adults with Generalized Anxiety Disorder (GAD)—a condition characterized by fluctuating or episodic manifestations. Research examined how symptoms changed over defined time intervals using standardized anxiety rating scales. Studies monitored outcomes related to systemic or functional imbalance by tracking changes in anxiety severity, and also monitored outcomes related to tolerability that occurred during the study period.

These studies described how symptoms were reported in the observed populations over short intervals, typically between six and eight weeks. The findings describe patterns observed in the studies in these short-term studies, and the data show patterns related to outcomes related to systemic or functional imbalance. Post-marketing data, collected over longer periods, also contribute to the broader evidence landscape by monitoring physiological strain or stress over extended timeframes.


What is Still Uncertain About Фибралакс

Evidence highlights what is known—and what is still uncertain—about Фибралакс. Long-term effects are not fully established, particularly regarding the outcomes related to daily functioning or activity level over many years of use. Follow-up durations were limited in many of the key studies. The measurements varied across some individual studies, and comparative evidence is lacking in some areas, such as direct comparisons to all similar existing treatments. Research provides context but not individual predictions, and studies contribute to the broader evidence landscape but do not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Фибралакс (FAQ)

Q: Can Фибралакс be taken with food?

Official guidance on the administration of this medicine states that doses should preferably be taken after meals. This timing helps integrate the bulk-forming agent into the digestive process. The medicine must always be consumed with an adequate amount of fluid.

Q: Does the time of day I take Фибралакс matter for its effectiveness?

The standard regimen, as described in official product information, is typically scheduled for both morning and evening administration. A safety constraint requires that the last dose of the day not be taken immediately before going to sleep.

Q: Is Фибралакс safe to use for older adults?

Official documents note that dosing is not typically modified for the elderly population compared to adults. However, treatment for older adults and debilitated patients requires medical supervision. Medical supervision is required due to the potential for certain complications, which is a consideration for all bulk-forming agents.

Q: Does Фибралакс interact with herbal supplements?

As a bulk-forming agent, regulatory documents state that Фибралакс may delay or reduce the absorption of other substances. This includes certain minerals and vitamins often found in supplements. Because of this physical effect, a separation of dosing times is a general requirement to mitigate the potential for reduced exposure.

Q: Does Фибралакс have known interactions with common painkillers like paracetamol?

While paracetamol (acetaminophen) is not specifically listed as an interacting substance like cardiac or thyroid medicines, the mandatory timing separation rule applies to virtually all oral medications. The mandatory timing separation rule applies, requiring these types of medicines to be taken separately from Фибралакс.

Q: Can people with kidney issues typically use Фибралакс?

Official product information notes that the medicine contains potassium. For this reason, use must be taken into consideration by patients with reduced kidney function or those on a controlled potassium diet. Consultation with a healthcare provider can determine the appropriate use under these circumstances.

Q: Is Фибралакс a type of antibiotic?

No, according to official classification, Фибралакс is a bulk-forming laxative. It is also classified as a herbal medicinal product due to its natural, plant-based origin. Its action is physical and localized within the gut, not systemic like an antibiotic.

Q: Does Фибралакс cause dependency if used for a long time?

The active ingredient has a profile that is considered suitable for long-term use in clinical contexts. This is due to its physical mechanism of action and low toxicity profile. While the final long-term effects over many years of use are not fully established, the nature of the drug is generally supportive.

Q: What's the difference between Фибралакс and a regular vitamin supplement?

Фибралакс is classified as a bulk-forming laxative with the purpose of supporting regular bowel function through a physical mechanism. This classification places it in a different regulatory and functional class from nutritional products like a vitamin supplement, which are intended to provide dietary intake of specific nutrients.

Q: Is it normal to feel a mild change in digestion when starting Фибралакс?

Yes, official documents note that common effects, such as flatulence and abdominal distension (bloating), occur frequently during the initial few days of treatment. These effects are typically noted to diminish with continued use of the medicine.

Q: Can teenagers use Фибралакс?

Official rules indicate that adults and adolescents over 12 years of age are generally considered eligible for use. Specific eligibility requirements and dosing instructions for all age groups are detailed in the official product documents.

Q: Is Фибралакс available without a prescription in some places?

The active ingredient in the medicine is commonly available over the counter (OTC) in many regulatory jurisdictions. It is often found in addition to being available on prescription, depending on the specific formulation and regional regulations.

Q: Does Фибралакс affect the absorption of food nutrients?

Official warnings note that the medicine may delay or reduce the absorption of certain vitamins and minerals present in the digestive tract. This potential interaction is why timing separation from other oral intake is generally required.

Q: What is the risk of a serious allergic reaction to Фибралакс?

Hypersensitivity reactions, including severe reactions like anaphylaxis, are possible but have been reported rarely in regulatory surveillance. Official information also notes that the risk of sensitization may be higher for individuals with occupational exposure to the powder form, such as those working in manufacturing.

Q: Does Фибралакс contain gluten or common allergens?

Official information indicates that the husk itself contains potent allergens. Furthermore, specific excipients are listed in the product composition, such as Aspartame, which is a source of phenylalanine and is listed as a precaution for people with phenylketonuria.

Q: Is Фибралакс meant for continuous use or short periods?

The active ingredient is considered suitable for long-term use in clinical contexts. Official documentation also refers to short-term use, noting that consultation with a healthcare professional is advised if the established effect is not achieved within 3 days.

Q: What should I do if I forget to take a dose of Фибралакс?

Regulatory guidance suggests that if a dose is missed, it can be taken as soon as it is remembered. However, if the time is very close to the next scheduled dose, the missed dose should be omitted instead. Regulatory guidance describes omitting the missed dose if the next dose time is near, noting that taking two doses together is not the prescribed approach.

Q: Are there different strengths or formulations of Фибралакс?

The medicine is generally supplied as granules or powder. Regulatory documents specify the standard active ingredient dose. Further details on available formulations are typically found in the full product information.

Q: Are there any known physical symptoms that indicate Фибралакс is working?

The medicine's mechanism of action is physical, primarily intended to increase the mass and pliability of the stool. This increase in volume then triggers the intestinal peristaltic reflex, which is the sequence of muscle contractions that facilitate movement.

Q: Are there specific dietary changes recommended while taking Фибралакс?

A fundamental requirement for safe use is to maintain adequate fluid intake, as this is crucial for the bulk-forming agent to function correctly and avoid obstruction. This includes consuming the dose with a full glass of water or other suitable liquid.

Q: What types of food or drinks are specifically mentioned in interactions with Фибралакс?

The medicine must be prepared and consumed in a liquid suspension using water or another suitable fluid. Additionally, official documents state that doses are typically taken after meals. The timing separation rules apply to all oral medications, but not specific food types other than the timing context.

Q: Is Фибралакс a preventative medicine?

Official documentation describes the function of the medicine as supporting the restoration of natural intestinal function and promoting regularity. This is a supportive role, which is distinct from a claim of preventing disease or future health conditions.

Q: Is there a specific period during which side effects are most likely to appear?

Yes, regulatory information specifies that common effects, such as flatulence and abdominal distension, are noted to occur frequently during the initial few days of treatment. These side effects typically diminish with continued use.

Q: What do researchers say about the long-term safety profile of Фибралакс?

Research has examined the long-term safety profile of the active ingredient. Evidence indicates that the majority of adverse effects recorded were mild. However, official summaries also state that long-term effects regarding certain patient outcomes over many years of use are not fully established.

Q: Is Фибралакс considered a scheduled or controlled substance?

No, regulatory bodies responsible for drug classification, such as the FDA, confirm that the active ingredient is not classified as a controlled or scheduled substance.

How should Фибралакс be stored and disposed of?

Storage and Handling Requirements

Storage Classification Requirement
Temperature Range Store at room temperature, typically 15 C to 30 C (59 F to 86 F). Do not store above 30 C.
Container Protection Keep the product in the original container and ensure it remains tightly closed to protect it from moisture.
Handling Restriction Protect from moisture and do not refrigerate or freeze. The product must be stored out of the sight and reach of children.

Disposal Instructions

Disposal Method Regulatory Guidance
Expired/Unused Product Dispose of according to local regulations or a drug take-back program if available.
Environmental Rule Do not dispose of via wastewater (do not flush down the toilet) unless specifically instructed by the regulator.

These official regulatory requirements are necessary to preserve the stability and integrity of the bulk-forming powder formulation, preventing premature hydration and clumping.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Фибралакс found in:

A-Z Index: